Effect of lipoic acid combined with alendronate sodium on bone mineral density,bone metabolism indexes and pain degree in patients with postmenopausal osteoporosis
Objective To investigate the effect of lipoic acid(LA)combined with alendronate sodium on bone mineral density,bone metabolism indexes and pain degree in patients with postmenopausal osteoporosis(PMOP).Methods A total of 106 patients with PMOP admitted to Chuzhou First People's Hospital from January to December 2022 were enrolled as the research objects.According to random number table method,they were divided into the experimental group(n=53,oral LA and alendronate sodium)and the control group(n=53,alendronate sodium).The clinical curative effect,changes in inflammatory factors(tumor necrosis factor-α(TNF-α),insulin-like growth factor-1(IGF-1),interleukin-6(IL-6)),bone mineral density(right femoral neck,lumbar vertebra(L1-L4)bone),bone metabolism indexes(osteocalcin(BGP),type I C-tenninal cross linked peptide(CTX-I),receptor activator of NF-кB ligand(RANKL),osteoprotectin(OPG))and pain degree before and after treatment were compared between the two groups.Results After treatment,the clinical response rate was higher in the experimental group than in the control(94.34%vs 81.13%,χ2=4.296,P＜0.05).The levels of TNF-α and IL-6 were decreased in both groups and they were lower in the experimental group than in the control((242.32±40.31)pg·mL-1,(3.45±1.31)pg·mL-1 vs(274.53±41.32)pg·mL-1,(4.13±1.22)pg·mL-1,t=4.062,2.765,both P＜0.05).The IGF-1 level was increased after treatment and it was higher in the experimental group than in the control((276.42±75.31)pg·mL-1 vs(167.32±41.43)pg·mL-1),showing significant difference(t=9.241,P＜0.05).The bone mineral density values of right femoral neck and lumbar vertebra(L2～4)were increased in both groups and they were higher in the experimental group than in the control((0.83±0.12)g·cm-1,(0.94±0.15)g·cm-1 vs(0.75±0.09)g·cm-1,(0.87±0.13)g·cm-1),demonstrating significant difference(t=3.883,2.329,both P＜0.05).The levels of CTX-1 and RANKL were decreased in both groups and they were lower in the experimental group than in the control((0.18±0.05)ng·mL-1,(6.32±0.85)ng·mL-1 vs(0.24±0.08)ng·mL-1,(8.53±1.31)ng·mL-1,t=4.258,9.468,both P＜0.05).However,the levels of BGP and OPG were increased and they were higher in the experimental group than in the control((27.57±5.32)g·L-1,(265.77±36.65)ng·mL-1 vs(21.49±5.31)g·L-1,(240.67±43.55)ng·mL-1),revealing statistically significant difference(t=5.360,2.934,both P＜0.05).After treatment,the VAS scores were decreased in both groups and they were remarkably lower in the experimental group than in the control((2.02±0.77)points vs(2.82±1.81)points,t=2.740,P＜0.05).The difference in incidence of adverse reactions was not statistically significant between the two groups(9.43%vs 5.66%,P＞0.05).Conclusion LA combined with alendronate sodium can reduce inflammation,increase bone mineral density,improve bone metabolism and relieve pain in PMOP patients.Furthermore,it is of high safety.
MenopauseBone mineral densityLipoic acidBone metabolism indexInflammatory factorAlendronate sodium
万方数据
维普
